ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 31 Aug 2022
Last Updated on 31 Aug 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:

  • Gemtuzumab ozogamicin 5 mg powder for concentrate for solution for infusion in combination with daunorubicin and cytarabine for patients with previously untreated de novo CD33-positive acute myeloid leukaemia (AML), if they:

    • do not have acute promyelocytic leukaemia;
    • only start induction therapy while waiting for cytogenetic test results or after confirming favourable, intermediate or unknown (due to inconclusive test results) cytogenetic risk, and
    • start consolidation therapy after confirming favourable, intermediate, or unknown cytogenetic risk.

Funding status

Gemtuzumab ozogamicin 5 mg powder for concentrate for solution for infusion is recommended for inclusion on the Cancer Drug List (Medication Assistance Fund and MediShield Life monthly claim limit of SG$3200) for the abovementioned indication from 1 September 2022.


Gemtuzumab ozogamicin for untreated de novo CD33+ acute myeloid leukaemia (31 Aug 22) Gemtuzumab ozogamicin for treating de novo CD33+ acute myeloid leukaemia-PES (31 Aug 22)